Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 9/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 4/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26660843 | 1.00 | CA1 (0.46) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL26660847 | 1.00 | CA1 (0.46) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL2861782 | 0.88 | CA1 (0.52) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL22433832 | 0.87 | CA1 (0.45) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL30695367 | 0.86 | CA1 (0.44) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL11127933 | 0.86 | CA1 (0.44) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL30699304 | 0.86 | CA1 (0.44) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL15604758 | 0.85 | CA1 (0.44) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL30980418 | 0.84 | CA1 (0.45) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL22806217 | 0.84 | CA1 (0.45) | CA1CA2CA7CTSKCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4651948-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4651945-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4651951-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4651946-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4651953-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4651947-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-12384797-B2 | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia | PTC THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| WO-2024155837-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| WO-2024155847-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| WO-2024155836-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| WO-2024155840-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| WO-2024155846-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| WO-2024155838-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| WO-2022253294-A1 | PYRIDONE COMPOUND HAVING INTEGRASE INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2022-12-08 | — | — | WO | disclosed |
| US-20220135586-A1 | THIOENO[3,2-B] PYRIDIN-7-AMINE COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | PTC THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| CN-113795304-A | Thieno [3,2-B ] pyridin-7-amine compounds for the treatment of familial autonomic nervous dysfunction | PTC医疗公司 | 2021-12-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135586-A1 | THIOENO[3,2-B] PYRIDIN-7-AMINE COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | SF3B5, SF3B2, SF3B1 | CA1 4838/4885CA2 4657/4885CA7 4739/4885 |
| US-12384797-B2 | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia | SF3B5, SF3B2, SF3B1 | CA1 4838/4885CA2 4657/4885CA7 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.